北京德恒律师事务所 关于北京热景生物技术股份有限公司 2025 年第四次临时股东会的 法律意见 北京市西城区金融街 19 号富凯大厦 B 座 12 层 电话:010-52682888 传真:010-52682999 邮编:100033 北京德恒律师事务所 关于北京热景生物技术股份有限公司 2025 年第四次临时股东会的法律意见 北京德恒律师事务所 关于北京热景生物技术股份有限公司 2025年第四次临时股东会的 德恒 01G20250768 号 致：北京热景生物技术股份有限公司 北京德恒律师事务所（以下简称"本所"）受北京热景生物技术股份有限公 司（以下简称"公司"）委托，本所指派律师（以下简称"本所承办律师"）出席 了公司2025年第四次临时股东会（以下简称"本次股东会"），对公司本次股东会 的召集与召开程序、出席会议人员的资格与召集人的资格、会议表决程序与表决 结果等有关事项出具见证意见。 本法律意见根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上市 公司股东会规则》（以下简称"《股东会规则》"）等有关法律、法规和规范性文件， 以及《北京热景生物技术股份有限公司章程》（以下简称"《公司章程》"） ...

Core Viewpoint - The stock of Beijing Hotgen Biotech Co., Ltd. increased by 5.32% on November 10, reaching a price of 143.50 yuan per share, with a trading volume of 276 million yuan and a turnover rate of 2.11%, resulting in a total market capitalization of 13.304 billion yuan [1]. Company Overview - Beijing Hotgen Biotech Co., Ltd. was established on June 23, 2005, and went public on September 30, 2019. The company is located in the Daxing District of Beijing and specializes in the research, development, production, and sales of in vitro diagnostic reagents and instruments [1]. - The revenue composition of the company includes: 70.87% from testing reagents, 19.79% from testing instruments, 8.17% from other sources, and 1.17% from biological raw materials [1]. Fund Holdings - According to data, one fund under Huaxia Fund has a significant holding in Hotgen Biotech. The Huaxia SSE STAR 200 ETF (588820) increased its holdings by 28,000 shares in the third quarter, bringing the total to 29,600 shares, which accounts for 1.06% of the fund's net value, making it the tenth largest holding [2]. - The Huaxia SSE STAR 200 ETF (588820) was established on December 23, 2024, with a latest scale of 476 million yuan. Year-to-date, it has achieved a return of 53.55%, ranking 500 out of 4217 in its category, and a cumulative return of 52.86% since inception [2]. Fund Manager Information - The fund manager of the Huaxia SSE STAR 200 ETF (588820) is Hualong. As of the report date, Hualong has been in the position for 3 years and 82 days, managing total assets of 35.957 billion yuan. The best fund return during this period was 107.73%, while the worst was -15.08% [3].

Core Viewpoint - The stock of Hotgen Biotech experienced a decline of 2.01% on November 7, with a current price of 136.99 CNY per share and a total market capitalization of 12.7 billion CNY. The company has seen a significant increase in stock price of 121.52% year-to-date, but has faced recent declines over various time frames [1][2]. Financial Performance - For the period from January to September 2025, Hotgen Biotech reported a revenue of 310 million CNY, representing a year-on-year decrease of 19.80%. The net profit attributable to shareholders was -109 million CNY, a significant decline of 168.12% compared to the previous year [2]. - Cumulative cash dividends since the A-share listing amount to 440 million CNY, with 17.34 million CNY distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Hotgen Biotech increased by 12.90% to 7,833, while the average circulating shares per person decreased by 11.43% to 11,835 shares [2]. - The top ten circulating shareholders include various funds, with notable changes in holdings: Huatai-PineBridge Innovation Medicine Mixed Fund reduced its holdings by 12.53%, while ICBC Frontier Medical Stock A increased its holdings by 50.00% [3]. Market Activity - The stock has been active on the trading board, appearing five times this year, with the most recent net purchase on July 4 amounting to 47.83 million CNY, accounting for 25.69% of total trading volume [1]. - The stock has experienced a decline of 14.38% over the last five trading days, 15.44% over the last 20 days, and 42.20% over the last 60 days [1]. Business Overview - Hotgen Biotech, established on June 23, 2005, and listed on September 30, 2019, specializes in the research, development, production, and sales of in vitro diagnostic reagents and instruments. The revenue composition includes 70.87% from testing reagents, 19.79% from testing instruments, 8.17% from other sources, and 1.17% from biological raw materials [1]. - The company operates within the pharmaceutical and biotechnology sector, specifically in medical devices and in vitro diagnostics, with involvement in concepts such as Alzheimer's, innovative drugs, antigen testing, and monkeypox [2].

Group 1 - The fourth extraordinary general meeting of shareholders for 2025 has been canceled due to the need for further optimization and improvement of the capital increase and equity incentive plan for Beijing Shunjing Biomedical Technology Co., Ltd. [2] - The original notice of the shareholders' meeting remains unchanged, except for the canceled proposal [2]. - The shareholders' meeting is scheduled to be held on November 10, 2025, at 14:30 at the company's meeting room in Beijing Daxing District [2]. Group 2 - The network voting system will be the Shanghai Stock Exchange's shareholder meeting network voting system, with voting available on the day of the meeting from 9:15 to 15:00 [3]. - The record date for shareholders to participate in the meeting remains unchanged [5]. - The proposals submitted for the shareholders' meeting have been approved by the company's board of directors and were disclosed on October 24, 2025 [6].

证券代码：688068 证券简称：热景生物 公告编号：2025-073 北京热景生物技术股份有限公司 关于2025年第四次临时股东会取消议案的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 股东会有关情况 1、 股东会的类型和届次： 2025年第四次临时股东会 | 股份类别 | | 股票代码 | 股票简称 | 股权登记日 | | --- | --- | --- | --- | --- | | A | 股 | 688068 | 热景生物 | 2025/11/4 | 二、 取消议案的情况说明 1、 取消议案名称 1、 现场会议召开的日期、时间和地点 召开日期、时间：2025 年 11 月 10 日 14 点 30 分 召开地点：：北京市大兴区中关村科技园区大兴生物医药产业基地庆丰西路 55 号公司三层会议室 2、 网络投票的系统、起止日期和投票时间。 | 序号 | 议案名称 | | --- | --- | | 1 | 《关于参股公司增资扩股实施股权激励暨关联交易的议案》 | 2、 取消议案原因 关于北京舜景生物医药技 ...

北京热景生物技术股份有限公司 2025 年第四次临时股东会会议资料 证券代码：688068 证券简称：热景生物 北京热景生物技术股份有限公司 2025 年第四次临时股东会会议资料 2025 年 11 月 一、为确认出席会议的股东或其代理人或其他出席者的出席资格，会议工作人员 将对出席会议者的身份进行必要的核对工作，请被核对者给予配合。 | 目 录 | 1 | | --- | --- | | 2025 年第四次临时股东会会议须知 | 2 | | 2025 年第四次临时股东会会议议程 | 4 | | 2025 年第四次临时股东会会议议案 | 6 | 北京热景生物技术股份有限公司 2025 年第四次临时股东会会议资料 北京热景生物技术股份有限公司 2025 年第四次临时股东会会议须知 为了维护全体股东的合法权益，确保股东会的正常秩序和议事效率，保证大会的 顺利进行，根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司股 东会规则》以及《北京热景生物技术股份有限公司章程》《北京热景生物技术股份有 限公司股东会议事规则》等相关规定，北京热景生物技术股份有限公司（以下简称 "公司"）特制定本次股东会会议须知： ...

Core Viewpoint - The company Hotgen Biotech (688068.SH) announced that its significant associate, Hangzhou Aorui Biotechnology Co., Ltd., has recently obtained a Class III medical device registration certificate in China for a gene methylation detection kit used in the auxiliary diagnosis of suspected primary liver cancer [1] Group 1 - The product name is TSPYL5, RASSF1A, DAB2IP, OTX1, PTPN18, HIST1H3G gene methylation detection kit (PCR fluorescence probe method) [1] - The kit is designed for in vitro qualitative detection of methylated TSPYL5, RASSF1A, DAB2IP, OTX1, PTPN18, HIST1H3G genes in human plasma [1] - The product is applicable for clinical auxiliary diagnosis of suspected primary liver cancer [1]

证券代码：688068 证券简称：热景生物 公告编号：2025-072 北京热景生物技术股份有限公司 关于公司参股公司近期获得资质情况的自愿披露 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京热景生物技术股份有限公司（以下简称"公司"）重要参股公司杭州翱锐 生物科技有限公司（以下简称"翱锐生物"）近期获得国内 III 类医疗器械注册证。 相关信息如下： 一、获得资质的具体情况 | | TSPYL5、RASSF1A、DAB2IP、 | | 国械注准 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | | OTX1、PTPN18、HIST1H3G | 基因甲 | 20253402195 | III | 2025/10/30 | 2030/10/29 | 监督管理局 | | 序号 1 | 产品名称 基化检测试剂盒（PCR 荧光探针法) | | 注册证号 | 类别 | 发证日期 | 有效期至 | 发证机构 国家药品 | 产品预期用途：本产品用于体外 ...

Core Viewpoint - The company, Hotgen Biotech (688068), announced that its important associate, Aorui Biotech, has recently obtained a Class III medical device registration certificate in China for a gene methylation detection kit, which is used for the auxiliary diagnosis of suspected primary liver cancer [1] Group 1 - The registered product includes TSPYL5, RASSF1A, DAB2IP, OTX1, PTPN18, and HIST1H3G gene methylation detection kits using PCR fluorescence probe method [1] - The product is applicable for clinical auxiliary diagnosis of suspected primary liver cancer [1]

Core Viewpoint - The announcement highlights that a significant associate company of the firm, Aorui Biotech, has recently obtained a Class III medical device registration certificate in China for a product that includes six gene methylation detection kits, enhancing the company's cancer detection product offerings [1] Group 1: Product Registration Details - The product is identified as TSPYL5 and five other gene methylation detection kits [1] - The registration certificate number is Guo Xie Zhu Ren 20253402195, issued on October 30, 2025, and valid until October 29, 2030 [1] - The issuing authority is the National Medical Products Administration of China [1] Group 2: Product Application and Market Impact - The product is intended for in vitro qualitative detection of related genes in human plasma, specifically for assisting in the diagnosis of suspected primary liver cancer [1] - The certification expands the company's range of tumor detection products and enhances its liver cancer detection product line [1] - However, the sales of the product may be influenced by multiple factors, leading to uncertainties [1]